Hepatic steatosis and type 2 diabetes: Current and future treatment considerations

John Richard, Ildiko Lingvay

Research output: Contribution to journalReview articlepeer-review

37 Scopus citations


Hepatic steatosis, considered the first step in the pathophysiologic continuum of non-alcoholic fatty liver disease, is estimated to afflict 30% of the US population and over 75% of patients with Type 2 diabetes. Given the expected rise in the prevalence of obesity and Type 2 diabetes in the following decades, hepatic steatosis will, if not already, become an epidemic. The consequences of hepatic steatosis are numerous, and range from progression to chronic liver disease, with its associated morbidity and mortality, to worsening insulin resistance and Type 2 diabetes, as well as being an independent contributor to cardiovascular disease. All such consequences are more likely to occur in patients with Type 2 diabetes who are already at high risk of cardiovascular events. In this article we review the evidence behind the available therapeutic options for hepatic steatosis, and identify challenges and unmet needs in the field.

Original languageEnglish (US)
Pages (from-to)321-328
Number of pages8
JournalExpert Review of Cardiovascular Therapy
Issue number3
StatePublished - Mar 2011


  • FXR agonists
  • Type 2 diabetes
  • hepatic steatosis
  • incretin mimetics
  • metabolic syndrome
  • metformin
  • non-alcoholic fatty liver disease
  • obesity
  • thiazolidinediones

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Hepatic steatosis and type 2 diabetes: Current and future treatment considerations'. Together they form a unique fingerprint.

Cite this